A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.

@article{Shah2006API,
  title={A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.},
  author={Manisha Hasmukhray Shah and Aharon G. Freud and Don Michael Benson and Amy K. Ferkitich and Bruce J. Dezube and Zale P. Bernstein and Michael A. Caligiuri},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 13},
  pages={3993-6}
}
PURPOSE Ultra low doses of interleukin-2 (IL-2) can activate the high-affinity IL-2 receptor constitutively expressed on CD56(bright) natural killer (NK) cells, the CD34+ NK cell precursor, and CD4+ CD25+ regulatory T cells (Tregs) in vivo. We have previously shown synergy between IL-2 and stem cell factor (SCF) in the generation of CD56(bright) NK cells from CD34+ hemopoietic progenitor cells in vitro and showed synergistic NK cell expansion in an in vivo preclinical model. To determine the… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 21 references

A human CD 34 ( + ) subset resides in lymph nodes and differentiates into CD 56 bright natural killer cells

AG Freud, B Becknell, S Roychowdhury
Immunity • 2005

Lympho - penia and interleukin - 2 therapy alter homeostasis of CD 4 + CD 25 + regulatory T cells

H Zhang, KS Chua, M Guimond
J Clin Invest • 2005

In vivo expansion of CD 4 + CD 45 RO  CD 25 + Tcells expressing foxP 3 in IL - 2 treated HIV - infected patients

I Sereti, H Imamichi, V Natarajan
Common Toxicity Criteria manual , version 2 . 0 • 1999

Flt 3 ligand promotes the generationof a distinct CD 34 ( + ) human natural killer cell progenitor that responds to interleukin - 15

H Yu, TA Fehniger, P Fuchshuber
Blood • 1998

Similar Papers

Loading similar papers…